XML 20 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1Close
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Assets:    
Cash and cash equivalents $ 9,801 $ 8,196
Investments 3,288 3,259
Accounts receivable, net 32,217 35,227
Inventories 16,346 18,025
Other current assets 5,821 3,151
Total current assets 67,473 67,858
Long-term investments 24,074 23,019
Property and equipment, net 13,037 13,183
Operating lease right-of-use assets 17,045 17,252
Goodwill 91,272 91,272
Intangible assets, net 28,770 29,234
Separate accounts assets 3,271 3,250
Other assets 4,801 4,660
Total assets 249,743 249,728 Close
Liabilities:    
Accounts payable 13,717 14,897
Pharmacy claims and discounts payable 22,289 22,874
Health care costs payable 14,368 12,049
Policyholders’ funds 1,081 1,326
Accrued expenses 22,350 22,189
Other insurance liabilities 1,158 1,141
Current portion of operating lease liabilities 1,906 1,741
Short-term debt 2,719 200
Current portion of long-term debt 3,731 2,772
Total current liabilities 83,319 79,189
Long-term operating lease liabilities 15,742 16,034
Long-term debt 57,694 58,638
Deferred income taxes 4,184 4,311
Separate accounts liabilities 3,271 3,250
Other long-term insurance liabilities 5,178 5,459
Other long-term liabilities 6,205 6,211
Total liabilities 175,593 173,092 Close
Shareholders’ equity:    
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding 0 0
Common stock, par value $0.01: 3,200 shares authorized; 1,771 shares issued and 1,252 shares outstanding at March 31, 2024 and 1,768 shares issued and 1,288 shares outstanding at December 31, 2023 and capital surplus 49,209 48,992
Treasury stock, at cost: 519 shares at March 31, 2024 and 480 shares at December 31, 2023 (36,773) (33,838)
Retained earnings 61,873 61,604
Accumulated other comprehensive loss (341) (297)
Total CVS Health shareholders’ equity 73,968 76,461
Noncontrolling interests 182 175
Total shareholders’ equity 74,150 76,636 Close
Total liabilities and shareholders’ equity $ 249,743 $ 249,728